Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma
详细信息 查看全文
- 作者：Jing Tian ; Ming Shang ; Sheng-Bin Shi ; Yong Han…
- 关键词：Advanced esophageal cancer ; Cetuximab ; Pemetrexed ; Second ; line therapy
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2015
- 出版时间：October 2015
- 年：2015
- 卷：76
- 期：4
- 页码：829-834
- 全文大小：471 KB
- 参考文献：1.Tang WR, Fang JY, Wu KS et al (2014) Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012. Asian Pac J Cancer Prev 15:6929鈥?934CrossRef PubMed
2.Hofstetter W, Swisher SG, Correa AM et al (2002) Treatment outcomes of resected esophageal cancer. Ann Surg 236:376鈥?84PubMed Central CrossRef PubMed
3.A-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435鈥?442CrossRef
4.Lorenzen S, Schuster T, Porschen R et al (2009) Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20:1667鈥?673CrossRef PubMed
5.Thallinger CM, Raderer M, Hejna M (2011) Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29:4709鈥?714CrossRef PubMed
6.Liao Z, Cox JD, Komaki R (2007) Radiochemotherapy of esophageal cancer. J Thorac Oncol 2:553鈥?68CrossRef PubMed
7.Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567鈥?78CrossRef PubMed
8.Safran H, Suntharalingam M, Dipetrillo T et al (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391鈥?95CrossRef PubMed
9.Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404鈥?17CrossRef PubMed
10.Tian GY, Miu M, Huang XE (2014) Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev 15:8475鈥?478CrossRef PubMed
11.Li BS, Gong HY, Huang W et al (2011) Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 24(4):251鈥?57CrossRef PubMed
12.Jatoi A, Soori G, Foster NR et al (2010) Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol 5:1994鈥?998CrossRef PubMed
13.Katipamula R, Jatoi A, Foster NR et al (2008) Pemetrexed, carboplatin, and concomitant radiation followed by surgery for locally advanced esophageal cancer: results of a planned interim toxicity analysis of North Central Cancer Treatment Group Study N044E. Clin Med Oncol 2:223鈥?25PubMed Central PubMed
14.Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419鈥?23CrossRef PubMed
15.Syrigos KN, Zalonis A, Kotteas E et al (2008) Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev 27:273鈥?88CrossRef PubMed
16.Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955鈥?59CrossRef PubMed
17.Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265鈥?272CrossRef PubMed
18.Shirakawa T, Kato K, Nagashima K et al (2014) A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol 74(6):1207鈥?215CrossRef PubMed
19.Jin J, Xu X, Wang F et al (2009) Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 4(8):1017鈥?021CrossRef PubMed
20.Airoldi M, Cortesina G, Giordano C et al (2003) Docetaxel and vinorelbine an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 20(1):19鈥?4CrossRef PubMed
21.Li X, Lin W, Wang H et al (2013) Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. Med Oncol 30(4):746CrossRef PubMed
22.Akutsu Y, Kono T, Uesato M et al (2013) S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. Oncology 84(5):305鈥?10CrossRef PubMed
23.Chan JA, Blaszkowsky LS, Enzinger PC et al (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 6:1367鈥?373CrossRef
24.Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparitieson premature cancer deaths. CA Cancer J Clin 61:212鈥?36CrossRef PubMed
25.Lordick F (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):490鈥?99CrossRef PubMed
26.Janjigian YY (2012) Phase II trial of cetuximab plus cisplatin and irinotecanin patients with cisplatin and irinotecan-refractory metastatic esopha-gogastric cancer. Am J Clin Oncol 37(2):126鈥?30CrossRef
27.Waddell T (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):481鈥?89PubMed Central CrossRef PubMed
28.Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281鈥?97CrossRef PubMed
29.Hummel R, Watson DI, Smith C et al (2011) Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 15:429鈥?38CrossRef PubMed
30.Imanaka Y, Tsuchiya S, Sato F et al (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 56:270鈥?76CrossRef PubMed
31.Lynam-Lennon N, Reynolds JV, Marignol L et al (2012) MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl) 90:1449鈥?458CrossRef
32.Zhang BJ, Gong HY, Zheng F et al (2014) Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 7(9):6213鈥?218PubMed Central PubMed
33.Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, Stallings RL (2012) MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-尾 signalling pathway. Carcinogenesis 33:976鈥?85PubMed Central CrossRef PubMed
34.Tom茅 M, L贸pez-Romero P, Albo C, Sep煤lveda JC, Fern谩ndez-Guti茅rrez B, Dopazo A, Bernad A, Gonz谩lez MA (2011) miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 18:985鈥?95PubMed Central CrossRef PubMed - 作者单位：Jing Tian (1)
Ming Shang (1)
Sheng-Bin Shi (1)
Yong Han (1)
Jun Xu (1)
1. Department of Medical Oncology, Shan Dong Tumor Hospital, 440 Jiyan Road, Jinan, Shandong, People鈥檚 Republic of China - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Cancer Research
Pharmacology and Toxicology
Oncology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0843
文摘
Purpose The aim of this study was to evaluate the efficacy and toxicity of cetuximab and pemetrexed as the second-line treatment for advanced esophageal cancer patients, who had undergone treatment with the standard cisplatin and 5-FU regimens.